摘要
乳腺癌新辅助化疗(NAC)最初是指对局部晚期乳腺癌患者手术治疗之前所进行的辅助化疗,目前己将该治疗扩展至肿瘤较大的可手术的乳腺癌患者,以使肿瘤降期,进而达到保乳手术治疗的目的。随着新辅助化疗在乳腺癌患者中不断推广应用,使用传统方法和影像学评价预测新辅助化疗反应,未能提供准确和可靠的数据。因此临床实践中迫切需要一种能准确评价化疗后肿瘤变化的检查方法。最近,光散射断层成像,新的生物标志物,癌基因组分析引入到临床实践,产生了初步可喜的成果。本文对乳腺癌新辅助化疗的临床评价方法进行综述。
Neoadjuvant chemotherapy for breast cancer （BC） has been used as an initial treatment for patients with locally advanced BC before surgical resection. The use of this therapy has now been extended to patients with operable BC in an attempt to down-stage the tumors in order to successfully perform breast-conserving surgery. Traditional methods and image evaluation for predicting the effect of neoadjuvant chemotherapy have failed to provide accurate and reliable data. Therefore, a method of examination that can correctly assess the tumor changes after chemotherapy is urgently needed in clinical practice. Recently, light scattering laminagraphy, new biological markers and analysis of cancer genomes have been introduced to clinical practice, achieving promising preliminary outcomes. In this article, the clinical assessment of neoadjuvant chemotherapy for BC was reviewed.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2011年第7期415-418,共4页
Chinese Journal of Clinical Oncology
关键词
乳腺癌
新辅助化疗
影像学
Breast cancer
Neoadjuvant chemotherapy
Imaging
